Survival time for pancreatic cancer patients implanted with iodine-125 particles is variable, depending on the patient and the severity of the lesion, and usually ranges from a few months to 2 years. Pancreatic cancer is currently one of the most deadly malignant tumors in clinical practice. Early symptoms of pancreatic cancer are atypical, and when it is found, it is usually in the middle or late stage, so the chance of surgical resection is mostly lost. Comprehensive treatment is usually recommended, and the 5-year survival rate is usually no more than 10% when surgical treatment is combined with chemotherapy and radiotherapy. Some patients are found late and can no longer undergo surgical treatment, and can only undergo radiotherapy to control symptoms and prolong survival (e.g. iodine-125 particle implantation). The prognosis for patients with pancreatic cancer varies from person to person, and there are no universally accepted conclusions. According to some studies, the survival rates of 1, 2 and 3 years after diagnosis of pancreatic cancer are 21.5%, 6.0% and 4.0% respectively, and the overall median survival is only 5.5 months; and the prognosis of patients with advanced pancreatic cancer is even worse. It is recommended to go to regular hospitals to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, choose the appropriate treatment plan to prolong the survival period and improve the quality of life.